DE3586520T2 - Herpes simplex-virus als vektor. - Google Patents

Herpes simplex-virus als vektor.

Info

Publication number
DE3586520T2
DE3586520T2 DE8585303791T DE3586520T DE3586520T2 DE 3586520 T2 DE3586520 T2 DE 3586520T2 DE 8585303791 T DE8585303791 T DE 8585303791T DE 3586520 T DE3586520 T DE 3586520T DE 3586520 T2 DE3586520 T2 DE 3586520T2
Authority
DE
Germany
Prior art keywords
vector
herpes simplex
simplex virus
foreign gene
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8585303791T
Other languages
English (en)
Other versions
DE3586520D1 (de
Inventor
Bernard Roizman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arch Development Corp
Original Assignee
Pasteur Merieux Serum et Vaccines SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Merieux Serum et Vaccines SA filed Critical Pasteur Merieux Serum et Vaccines SA
Application granted granted Critical
Publication of DE3586520D1 publication Critical patent/DE3586520D1/de
Publication of DE3586520T2 publication Critical patent/DE3586520T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
DE8585303791T 1984-06-04 1985-05-30 Herpes simplex-virus als vektor. Expired - Lifetime DE3586520T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61693084A 1984-06-04 1984-06-04

Publications (2)

Publication Number Publication Date
DE3586520D1 DE3586520D1 (de) 1992-09-24
DE3586520T2 true DE3586520T2 (de) 1993-01-07

Family

ID=24471577

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8585303791T Expired - Lifetime DE3586520T2 (de) 1984-06-04 1985-05-30 Herpes simplex-virus als vektor.

Country Status (6)

Country Link
US (3) US5599691A (de)
EP (1) EP0176170B1 (de)
JP (2) JP2664892B2 (de)
AT (1) ATE79649T1 (de)
CA (1) CA1282721C (de)
DE (1) DE3586520T2 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859587A (en) * 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
CA1282721C (en) * 1984-06-04 1991-04-09 Bernard Roizman Herpes simplex virus as a vector
US5763269A (en) * 1985-09-06 1998-06-09 Syntro Corporation Recombinant infectious bovine rhinotrocheitis virus
SE8505027D0 (sv) * 1985-10-24 1985-10-24 Kabigen Ab A lytic virulent phage, a hostcell containing same and a process for protein production
WO1987004463A1 (en) * 1986-01-27 1987-07-30 Syntro Corporation Attenuated herpesviruses, herpesviruses which include foreign dna encoding an amino acid sequence and vaccine containing same
NZ220645A (en) * 1986-06-20 1989-10-27 Merck & Co Inc Modified varicella-zoster virus and its cultivation
FR2601689B1 (fr) * 1986-07-17 1992-10-16 Syntro Corp Herpes virus attenues, herpes virus qui renferment de l'adn etranger codant pour une sequence d'amino-acides, et vaccins les contenant
US5866136A (en) * 1986-08-01 1999-02-02 Commonwealth Scientific And Industrial Organisation Recombinant vaccine
NZ221298A (en) * 1986-08-01 1990-07-26 Commw Scient Ind Res Org A recombinant vaccine comprising an antigenic polypeptide component together with a lymphokine component
FR2602790B1 (fr) * 1986-08-13 1990-06-01 Transgene Sa Expression d'un antigene specifique de tumeur par un virus vecteur recombinant et utilisation de celui-ci pour le traitement preventif ou curatif de la tumeur correspondante
EP0277773A1 (de) * 1987-01-30 1988-08-10 The Board Of Trustees Of The Leland Stanford Junior University Mischcytomegalovirus und Vakzin
US5672344A (en) * 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
AU2888089A (en) * 1988-01-26 1989-07-27 Baylor College Of Medicine Infectious bovine rhinotracheitis virus insertion mutants, vaccines containing same, and methods for the production and use of same
GB8918616D0 (en) * 1989-08-15 1989-09-27 Univ Glasgow Herpes simplex virus type 1 mutant
US5849572A (en) * 1990-10-10 1998-12-15 Regents Of The University Of Michigan HSV-1 vector containing a lat promoter
US5849571A (en) * 1990-10-10 1998-12-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Latency active herpes virus promoters and their use
ES2191681T3 (es) * 1992-12-23 2003-09-16 Arch Dev Corp Promotores sinteticos de virus de herpes simple.
WO1994020517A1 (en) * 1993-03-08 1994-09-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Gene transfer for treating a connective tissue of a mammalian host
WO1996038546A1 (en) * 1995-06-01 1996-12-05 Merck & Co., Inc. Herpes simplex type 1 protease mutants and vectors
US6344445B1 (en) 1995-10-19 2002-02-05 Cantab Pharmaceutical Research Limited Herpes virus vectors and their uses
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
BR9813930A (pt) 1997-11-06 2006-12-19 Chiron Spa antìgeno neisserial
EP1047784B2 (de) 1998-01-14 2015-03-18 Novartis Vaccines and Diagnostics S.r.l. Antigene aus neisseria meningitidis
NZ532665A (en) 1998-05-01 2005-11-25 Inst Genomic Research Neisseria meningitidis antigens and compositions
US6783972B1 (en) 1998-09-22 2004-08-31 University Of Florida Research Foundation Methods for large-scale production of recombinant AAV vectors
US6774119B1 (en) * 1999-04-26 2004-08-10 Cedars-Sinai Medical Center Herpes simplex virus type 1 (hsv-1)-derived vector for selectively inhibiting malignant cells and methods for its use to treat cancers and to express desired traits in malignant and non-malignant mammalian cells
NZ571167A (en) 1999-04-30 2010-05-28 Novartis Vaccines & Diagnostic Fragments from Neisseria protein ORF 953 and their use in medicaments and diagnostic reagents
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
US6764675B1 (en) * 1999-06-08 2004-07-20 The Uab Research Foundation Herpes simplex virus expressing foreign genes and method for treating cancers therewith
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
EP2975127A1 (de) 1999-10-29 2016-01-20 GlaxoSmithKline Biologicals SA Neisseria antigenpeptide
EP2275129A3 (de) 2000-01-17 2013-11-06 Novartis Vaccines and Diagnostics S.r.l. Ergänzter Außenmembranvesikel-Impfstoff gegen Meningokokken
DE60131498T8 (de) * 2000-02-02 2009-01-29 Anges Mg Inc., Toyonaka VIRUSHÜLLENVEKTOR FüR DIE GENÜBERTRAGUNG
WO2001064920A2 (en) 2000-02-28 2001-09-07 Chiron Spa Hybrid expression of neisserial proteins
EP1950297A2 (de) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Zusammensetzungen und Verfahren zur Behandlung neoplastischer Erkrankungen mithilfe von Chemotherapie und Strahlungssensibilisatoren
SG165981A1 (en) 2000-10-27 2010-11-29 Chiron Srl Nucleic acids and proteins from streptococcus groups a & b
US7060442B2 (en) * 2000-10-30 2006-06-13 Regents Of The University Of Michigan Modulators on Nod2 signaling
JP4004952B2 (ja) 2000-11-28 2007-11-07 ザ ユニヴァーシティ オヴ シカゴ 心血管疾患治療のための遺伝的に操作されたヘルペスウイルス
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
EP2335723A1 (de) 2001-12-12 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Immunisierung gegen Chlamydia trachomatis
US8927251B2 (en) 2002-10-07 2015-01-06 The University Of Chicago Targeting of herpes simplex virus to specific receptors
US20070243170A1 (en) * 2002-10-07 2007-10-18 The University Of Chicago Targeting of Herpes Simplex Virus to Specific Receptors
US7550148B2 (en) * 2002-10-07 2009-06-23 The University Of Chicago Targeting of Herpes simplex virus to specific receptors
EP1549339B1 (de) * 2002-10-07 2019-06-05 University Of Chicago Targeting von herpes simplex virus an spezifische rezeptoren
PT2279746E (pt) 2002-11-15 2013-12-09 Novartis Vaccines & Diagnostic Proteínas de superfície de neisseria meningitidis
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
CN104292321A (zh) 2004-03-29 2015-01-21 株式会社嘉尔药物 新的半乳凝素9 突变体蛋白质及其用途
US7731952B2 (en) * 2004-06-24 2010-06-08 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
WO2006004878A1 (en) * 2004-06-29 2006-01-12 Wyeth Attenuated herpes simplex virus type-2, vectors thereof and immunogenic compositions thereof
SG10201912554TA (en) 2005-03-23 2020-02-27 Genmab As Antibodies against cd38 for treatment of multiple myeloma
ATE522541T1 (de) 2006-06-09 2011-09-15 Novartis Ag Bakterielle adhäsine konformere
PL2612868T3 (pl) 2007-11-01 2018-12-31 Astellas Pharma Inc. Immunosupresyjne polipeptydy i kwasy nukleinowe
PT2293804E (pt) 2008-05-29 2013-08-29 Univ Bologna Alma Mater Vírus herpes simplex (hsv) com tropismo modificado, suas utilizações e processo de preparação
EP3400292B1 (de) 2016-01-08 2020-08-26 Replimune Limited Verwendung eines onkolytisches virus zur behandlung von krebs
US10350542B2 (en) 2016-04-29 2019-07-16 General Electric Company Wet flue gas desulfurization system with zero waste water liquid discharge
US11911450B2 (en) 2017-07-13 2024-02-27 University Of Miami Method for managing pain
WO2023012385A1 (es) 2021-08-06 2023-02-09 Nabrawind Technologies, S.L. Transicion de laminados de material compuesto para pala modular

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769331A (en) * 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
EP0074808A3 (de) 1981-09-16 1984-07-04 University Patents, Inc. Rekombinantes Verfahren und Materialien
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4593002A (en) * 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
JPH0795954B2 (ja) * 1982-11-30 1995-10-18 アメリカ合衆国 外来性遺伝子発現のためのポックスウイルス組換え体の製造方法
US5288641A (en) * 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
CA1282721C (en) * 1984-06-04 1991-04-09 Bernard Roizman Herpes simplex virus as a vector

Also Published As

Publication number Publication date
EP0176170B1 (de) 1992-08-19
ATE79649T1 (de) 1992-09-15
US5599691A (en) 1997-02-04
JP2641688B2 (ja) 1997-08-20
JP2664892B2 (ja) 1997-10-22
CA1282721C (en) 1991-04-09
EP0176170A1 (de) 1986-04-02
US5846707A (en) 1998-12-08
JPS611390A (ja) 1986-01-07
JPH06181780A (ja) 1994-07-05
DE3586520D1 (de) 1992-09-24
US6071692A (en) 2000-06-06

Similar Documents

Publication Publication Date Title
DE3586520D1 (de) Herpes simplex-virus als vektor.
DK0738327T3 (da) Vært-vektorsystem til anvendelse ved genterapi
ATE130870T1 (de) Von adeno-assoziierte viren rekombinante vektoren.
PL333070A1 (en) Infectious clones of rna viruses and vaccines based on them
DK0500917T3 (da) Vacciner og fremgangsmåder baseret på rekombinante herpes simplex virusser.
HU9500870D0 (en) Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain
IL87041A0 (en) Induction of virus resistance in plants,recombinant dna molecules for use therein,their preparation and vectors and host cells comprising them
ES2196014T3 (es) Vectores de virus espumosos recombinantes para usos medicos y de diagtico y procedimiento de preparacion de vectores de virus espumosos recombinantes.
DK1021553T3 (da) Eukaryotisk genekspressionskassette og anvendelser deraf
DK0566554T3 (da) Fremstilling af rekombinante proteiner ved anvendelse af herpesviruspromotorer og VP16-transaktivatorer
EP0216564A3 (de) Infektiöses rekombinantes Virus, dieses enthaltende Impfstoffe gegen feline Leukämie und Verfahren zu deren Herstellung
WO1994013812A3 (en) Novel entomopoxvirus genes, proteins and methods of use thereof
EP0326127A3 (de) Infektiöse Rinder-Rhinotracheitis-Virus-Insertionsmutanten, sie enthaltende Impfstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung
DK498387A (da) Virus-dna-sekvens
DK0478696T3 (da) Effektiv fremgangsmåde til identificerbar udtrykkelse af ikke-selekterbare gener
EP0260090A3 (de) Expression von Hepatitis B-Virusantigenen von rekombinanten Bakulovirusvektoren
EP0276591A3 (en) Viral vector and recombinant dna coding for the p25 protein of the aids virus
Leung et al. A direct cloning-expression system for neutralization antigens of herpes simplex viruses.
TH33841A (th) รีคอมบิแนนท์เอวิพอคซ์ไวรัส การเพาะเลี้ยงเซลล์ที่ติดเชื้อไวรัสนี้ และวัคซีนสำหรับสัตว์ปีกที่อนุพัทธ์จากไวรัสนี้
SU1380209A1 (ru) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК PUR 291-HAV 22, КОДИРУЮЩАЯ СИНТЕЗ ГИБРИДНОГО ПОЛИПЕПТИДА АНТИГЕННЫХ ДЕТЕРМИНАНТ ВИРУСА ГЕПАТИТА А С β -ГАЛАКТОЗИДАЗОЙ

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ARCH DEVELOPMENT CORP., CHICAGO, ILL., US